Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HS024 is a synthetic cyclic peptide and a highly potent and selective antagonist of the melanocortin-4 receptor (**MC4 receptor**). It shows a *Ki* of 0.29 nM for MC4, with significantly lower affinities for MC5, MC3, and MC1 receptors, making it about 20-fold more selective for MC4. The peptide contains a 29-membered ring structure and includes modified amino acid residues. In preclinical studies, HS024 potently antagonizes the effects of alpha-MSH (alpha-melanocyte-stimulating hormone) on MC4 receptor signaling, thereby increasing food intake in rodents. It is primarily used as a research tool to study energy homeostasis, appetite regulation, and melanocortin receptor pharmacology[1][3][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on HS024.